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1. Introduction  
Infectious complications continue to be one of the major causes of morbidity and 
mortality in patients with chronic lymphocytic leukemia (CLL). The pathogenesis of 
infections in these patients is multifactorial (Wadhwa & Morrison, 2006). Predisposition to 
infection in CLL is mediated through various abnormalities including both the immune 
defects inherent in the primary disease (impairment in humoral and cellular immunity) 
and in the further immunosuppression related to management of CLL (Morra et al., 1999). 
Increased infectious events may arise from the multiple courses of immunosuppressive 
therapy and progressive deterioration of a patient's immune system over the course of 
disease (Elter et al., 2009). Hypogammaglobulinemia is an important predisposing factor 
for infection in patients with early-stage disease and for those treated with conventional 
alkylating agents (Wadhwa & Morrison, 2006). It is probably the most important immune 
defect increases the risk of severe bacterial infections and its frequency and severity has 
direct relationship with the duration of the disease (Morra, et al., 1999). The majority of 
disease-specific complications in CLL, notably infection and autoimmunity, relate to the 
underlying alterations in immune function. Both cellular and humoral immunity are 
impaired with qualitative and quantitative defects in B cells, T cells, NK cells, neutrophils 
and the monocyte/macrophage lineage. Virtually all patients have reduced 
immunoglobulin levels, even in early stages, and this is associated with an increased 
frequency and severity of infection (Dearden, 2008). The immunodeficiency chiefly 
manifests as hypogammaglobulinaemia but involves all elements of the immune system. 
It is caused by the interpolation of tumor cells among immunological cells and mediated 
by bi-directional cell contact and secretion of cytokines, which both sustain and invigorate 
the tumor and suppress immunity. CLL treatment generally makes the immunodeficiency 
worse (Hamblin & Hamblin, 2008). The proportion of patients treated with purine analogs 
and monoclonal antibodies such as rituximab and alemtuzumab is increasing. As a result 
of this therapy, these patients often experience profound and sustained T-cell 
immunodeficiency. Consequently, the spectrum of organisms causing infections in these 
patients is changing from common bacterial organisms to less common opportunistic 
pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses and Candida 
(Wadhwa & Morrison, 2006). The early recognition of infections as well as prophylactic 
administration of appropriate antibiotics has been the mainstay of managing infections in 
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patients with CLL. Hopefully, increasing understanding of the molecular events 
underlying the neoplastic change in CLL will lead to more targeted and less 
immunosuppressive therapeutic modalities (Ravandi & O'Brien S, 2006). 
2. Infectious diseases in chronic lymphocytic leukemia  
Patients with lymphoid malignancies such as chronic lymphocytic leukemia are at increased 
risk for infectious morbidity and mortality. Defects in cell-mediated immunity appear to be 
a major predisposing factor in these patients. An expanding spectrum of pathogens 
associated with lymphocytopenia and depletion of CD4 has been described in the setting of 
therapy with purine analogs. Infectious diseases in chronic lymphocytic leukemia are 
categorized as bacterial, viral, fungal and parasitic infection. CLL is characterized by 
progressive defects in humoral- and cell-mediated immunity. These defects are manifested 
as a propensity to develop infections with encapsulated, and less frequently, with gram-
negative enteric bacteria. In addition, reactivation of viruses such as herpesvirus is not 
uncommon. Treatment of the disease exacerbates immunosuppression by depleting immune 
effectors and broadening the spectrum of potentially offending pathogens (Wierda, 2003). 
Neutrophil count, serum immunoglobulin G level and granulocyte chemotaxis are 
predicting factors of susceptibility to infections. Phagocytosis and intracellular killing of 
granulocytes are intact in patients with CLL (Itälä et al, 1996, 1998). Over the past decade, 
the introduction of nucleoside analogs and monoclonal antibodies into the treatment of 
patients with CLL has resulted in higher rates and longer duration of response. This is a 
significant step towards achieving the ultimate goal of disease-eradication and improved 
survival. A continuing problem, however, is the susceptibility of these patients to infections. 
Profound dysregulation of the host immune system in patients with CLL and its impact on 
the clinical course of the disease are well established. A number of investigators have sought 
to identify the mechanisms underlying this innate immune dysfunction, which is further 
exacerbated by the actions of the potent therapeutic agents (Ravandi & O'Brien S, 2006). A 
characteristic spectrum of infectious complications has been described for specific treatment 
agents. With chlorambucil, most infections are bacterial in origin, caused by common Gram-
positive and -negative organisms. Recurrent infections are a hallmark, with the respiratory 
tract being the most common site of infection. The pathogenesis of infection with the purine 
analogues is related to the quantitative and qualitative T-cell abnormalities induced by these 
agents. Risk factors for infection identified in patients treated with fludarabine include 
advanced-stage disease, prior CLL therapy, response to therapy, elevated serum creatinine, 
hemoglobin < 12 g/dl, and decreased serum IgG. As compared with patients receiving 
chlorambucil, patients receiving fludarabine have more major infections and herpes virus 
infections. However, Pneumocystis, Aspergillus, and cytomegalovirus (CMV) infections are 
uncommon. The use of alemtuzumab is complicated by frequent opportunistic infections. 
CMV reactivation is especially problematic, occurring in 10%-25% of patients (Morrison, 
2009). The humanized, anti-CD52 monoclonal antibody alemtuzumab has shown notable 
activity for both untreated and fludarabine-refractory CLL. The antibody not only targets 
malignant cells but also affects normal, healthy immune cells. The cumulative effects of the 
malignancy and successive courses of treatments adversely impinge on a patient's defense 
response to certain bacterial, fungal, and viral infections (Elter et al., 2009). Severe 
lymphopenia is one of the most profound hematologic effects of alemtuzumab, often 
predisposing patients to infectious complications such as herpes simplex virus, 
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cytomegalovirus, and Pneumocystis jirovecii pneumonia. Opportunistic infections 
secondary to mycobacterial sources have been documented less frequently (Saadeh & 
Srkalovic, 2008). 
2.1 Bacterial infection 
Patients with chronic lymphocytic leukemia are at an increased risk for infections with 
bacteria which require complement for osponization (Heath & Cheson, 1985). Patients with 
chronic leukemias typically are affected by infections due to the underlying hematologic 
condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, 
particularly those agents that cause defects in cell-mediated immunity, the incidence of 
opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal 
infections also occur (Young, 2011). These defects are manifested as a propensity to develop 
infections with encapsulated bacteria, and less frequently, with gram-negative enteric 
bacteria. Bacterial pneumonia, urinary tract infection, sepsis, meningitis, typhlitis or 
neutropenic enterocolitis and soft tissue infections are common infections occur in CLL 
patients with bacterial source (Perkins et al., 2002). Staphylococcus spp., Streptococcus spp. 
(especially Streptoccoccus pneumonia) Enterococcus spp., Enterobacteriaceae, Hemophillus 
influenza, Pseudomonas spp. (especially Pseudomonas aeruginosa), Listeria 
monocytogenes, Nocardia, Vibrio vulnificus etc. are bacteria that cause infection in CLL 
patients (Travade et al, 1986; Barton & Ratard, 2006). Infections are one of the most 
important causes of mortality in CLL patients, and Streptococcus pneumoniae has been 
considered the most important single pathogen in this group (Sinisalo et al., 2007). In a 
survey on CLL patients with pneumonia, Pneumococcus was the most frequent agent 
followed by Pseudomonas aeruginosa, Pneumocystis carinii and Aspergillus fumigates. 
(Batlle et al., 2001). 
2.2 Epstein-Bar virus infection 
Epstein-Barr virus (EBV) is a gammaherpesvirus which infects greater than 90% of the 
world population. Infection is nonsymptomatic in healthy individuals, but has been 
associated with a number of lymphoproliferative disorders when accompanied by 
immunosuppression. Like all herpesviruses, EBV has both latent and lytic replication 
programs, which allows it to evade immune clearance and persist for the lifetime of the host 
(Bajaj et al., 2001). The most common primary symptoms of EBV infection are fever, skin 
eruption, lymphadenopathy, hepatosplenomegaly, eyelid edema, pharyngitis, cardiac 
arrhythmia and arthralgia (Li et al. 2004; C. Berger 2003). EBV can cause 
meningoencephalitis or central nervous system tumor-like lesion in immunocompromised 
patient (Khalil et al., 2008; Turkulov et al., 1999). This virus plays an important role in the 
etiology of nasopharyngeal carcinoma, adenocarcinoma of the parotid glands, gastric 
carcinoma, Burkitt's lymphoma and lymphoproliferative syndromes (Zahorodnia, 2011). 
EBV is pathogenically associated with a well defined group of lymphoid and epithelial 
tumors in which the virus directly drives transformation of infected cells. Recent evidence 
however indicates that this virus may infect a subpopulation of tumor cells in patients with 
chronic lymphocytic leukemia (Dordević, 2006). As one the most important clinical 
presentation of EBV and other herpesviruses is central nervous system (CNS) involvement; 
Rapid, sensitive and economical detection and identification of human herpesviruses as 
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causative agents of CNS infections is clinically important. The traditional methods for the 
detection of herpesviruses in CNS infections all suffer from limitations. Polymerase chain 
reaction (PCR) is the best laboratory test. Multiplex nested consensus PCR provide a rapid, 
sensitive and economical method for detection of viral infections and is applicable to small 
volumes of CSF samples (Tafreshi, 2005). The spectrum of drugs active against EBV remains 
very limited. Gancyclovir and acyclovir are used in medical practice. The search of new 
compounds active against EBV remains necessary (Zahorodnia, 2011). 
2.3 Cytomegalovirus infection 
Human cytomegalovirus (CMV) is one of herpesviruses that commonly infect humans. 
Advances in molecular virology coupled with improvements in diagnostic methods and 
treatment options have vastly improved ability to manage CMV infection, but many 
uncertainties remain, including the mechanisms of persistence and pathogenesis and its 
hypothesized roles in a variety of human illnesses (Boeckh & Geballe, 2011). It is a 
recognized cause of morbidity and mortality in immunocompromised individuals (Emery, 
2001). Primary infection with CMV is followed by persistence of the virus in a latent form. 
During life, the virus can reactivate, resulting in renewed shedding of the virus or 
development of disease. Significant progress has been made in detecting CMV, but in the 
immunocompromised patients, establishing the diagnosis of CMV infection can still be 
problematic (Vancíková & Dvorák, 2001). 
Cellular immune responses are important against virus infections (Sester et al, 2002). CMV 
infection causes significant morbidity and mortality in the setting of immunodeficiency 
(Ozdemir et al, 2002). It can cause serious clinical complications in eye (retinitis), lung, 
central nervous system and other organs in immunocompromised individuals (Bronke et al, 
2005; Reeves et al, 2005). For diagnosis the most sensitive molecular amplification methods 
such as PCR should be used. Treatment of infection depends mainly on the immune status 
of the host (Vancíková & Dvorák, 2001). The availability of sensitive diagnostic tests such as 
pp65 antigenemia has made the early diagnosis of CMV possible (Kusne et al, 1999). CMV 
should be suspected as a cause of pneumonia in immunocompromised patients and 
diagnosis may require invasive procedures bronchoalveolar lavage (BAL) and 
transbronchial lung biopsy (TBLB) may be required for diagnosis of CMV pneumonitis. 
(Yadegarynia et al, 2009). In immunocompetent patients only symptomatic treatment is 
recommended, while in immunocompromised patients antiviral therapy should be used. 
The most commonly used antiviral agents are: ganciclovir, foscarnet, cidofovir, 
valganciclovir and valaciclovir (Vancíková & Dvorák, 2001). Although it remains rare, 
ganciclovir-resistant CMV disease is increasingly seen in clinical practice, potentially 
fostered by the prolonged use of antiviral agents in high-risk patients. Treatment of drug-
resistant CMV is currently non-standardized and may include foscarnet, cidofovir, CMV 
hyperimmune globulins or leflunomide (Eid & Razonable, 2010).  
2.4 Herpes simplex virus infection 
Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) are alpha herpes viruses. Humans 
are the only natural host and they can be transmitted through oral or genital secretions. 
These viruses are ubiquitous all over the world, with different percentage rates (Dordević, 
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2006). They can infect both skin and nerves and develop latent infection within the dorsal 
root and trigeminal ganglia. Infection with these viruses is common and causes a wide range 
of clinical syndromes (Midak-Siewirska et al, 2010). HSV infections range in severity from 
common cutaneous outbreaks to life-threatening central nervous system and deep organ 
involvement (Higgins et al 1999). Atypical clinical manifestations of HSV may occur in 
immunocompromised patients. HSV-2 infection is responsible for significant neurological 
morbidity, perhaps more than any other virus (JR. Berger et al, 2008). Herpes esophagitis is 
common in immunosuppressed patients, but has rarely been reported in immunocompetent 
individuals, in whom it appears to be a self-limited illness (Canalejo Castrillero et al, 2010). 
Pneumonia, hepatitis, gasterointestinal involvement and disseminated infection may occur 
in immunocompromised patients (Longerich et al, 2005; Medlicott et al, 2005; Massler et al, 
2011). Multiple herpes virus co-infection (HSV and EBV) may occur in patients with chronic 
lymphocytic leukemia (Mercadal et al, 2006). HSV infections have a severe and rapidly 
progressive course especially in immunocompromised patients, leading to significant 
morbidity and mortality. Therefore, rapid and reliable laboratory diagnosis of HSV 
infections is important for initiation of early antiviral therapy. PCR, direct fluorescein 
antibody (DFA) methods and cell culture are used for diagnosis (Cordes et al, 2011). There is 
evidence that acyclovir is effective for preventing and treating HSV infections. There is no 
evidence that valaciclovir is more effective than acyclovir, or that a high dose of valaciclovir 
is better than a low dose (Nolan, 2009). Antiviral-resistant herpes virus infection has become 
a great concern for immunocompromised patients (Shiota et al, 2011). 
2.5 Hepatitis B virus infection 
Recent studies emphasize the risk of hepatitis B virus (HBV) reactivation among patients 
with hematologic malignancies of B lineage, in which HBV has been recently hypothesized 
to play a pathogenetic role. Occult HBV infection is significantly more prevalent among 
patients with CLL and may contribute to the susceptibility of patients with CLL to HBV 
reactivation, whether exposed or not to biological agents (Rossi et al, 2009). Chemotherapy-
induced HBV reactivation is a serious problem in chronic HBV carriers with hematologic 
malignancies. In Yağci’s study all patients with chronic lymphocytic leukemia experienced 
chemotherapy-induced HBV reactivation regardless of the chemotherapy regimen. CLL 
patients who are HBV carriers are at significant risk of chemotherapy-induced HBV 
reactivation (Yağci et al, 2006). Reactivation of HBV in HBsAg-positive patients is a well-
documented complication of cytotoxic or immunosuppressive therapy and has also been 
observed after treatment with rituximab (Heider et al, 2004). Patients may be treated with 
lamivudine or lamivudine plus adefovir dipivoxil combination therapy to control viral 
replication and allow for long-term anti-cancer chemotherapy (Cortelezzi et al, 2006). 
lamivudine is highly effective in inhibiting HBV proliferation and can be used to prevent 
HBV flare-up during chemotherapy in patients with positive HBs antigen (Heider et al, 
2004). 
2.6 Fungal infection 
Opportunistic fungal infection may occur in patient with CLL. Candida and Aspergillus are 
common fungi. Invasive Candida infections are important causes of morbidity and mortality 
in immunocompromised patients. The cornerstone of diagnosis remains the detection of the 
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organism by culture with identification of the isolate at the species level; in vitro susceptibility 
testing is mandatory for invasive isolates. Options for initial therapy of candidaemia and other 
invasive Candida infections in non-granulocytopenic patients include fluconazole or one of the 
three approved echinocandin compounds; liposomal amphotericin B. Voriconazole are 
secondary alternatives. In granulocytopenic patients, an echinocandin or liposomal 
amphotericin B is recommended as initial therapy. Indwelling central venous catheters serve 
as a main source of infection independent of the pathogenesis of candidaemia and should be 
removed whenever feasible. Dose reduction or discontinuation of pre-existing 
immunosuppressive treatment (particularly glucocorticosteroids) should be performed. 
Ophthalmoscopy is recommended prior to the discontinuation of antifungal chemotherapy to 
rule out endophthalmitis or chorioretinitis (Ruhnke et al, 2011). 
Morbidity and mortality caused by invasive Aspergillus infections are increasing. This is 
because of the higher number of patients with malignancies treated with intensive 
immunosuppressive therapy regimens as well as their improved survival from formerly fatal 
bacterial infections. Clinical diagnosis is based on radiologic findings and non-culture based 
diagnostic techniques such as galactomannan or DNA detection in blood or bronchoalveolar 
lavage samples. Most promising outcomes can be expected in patients at high risk for 
aspergillosis in whom antifungal treatment has been started pre-emptively, backed up by 
laboratory and imaging findings. The gold standard of systemic antifungal treatment is 
voriconazole, which has been proved to be significantly superior to conventional amphotericin 
B and has led to a profound improvement of survival rates in patients with cerebral 
aspergillosis. Liposomal amphotericin B at standard dosages appears to be a suitable alternative 
for primary treatment, while caspofungin, amphotericin B lipid complex or posaconazole have 
shown partial or complete response in patients who had been refractory to or intolerant of 
primary antifungal therapy. Combination therapy with two antifungal compounds may be a 
promising future strategy for first-line treatment (Maschmeyer et al, 2007). 
Cryptococcus neoformans is an important fungal pathogen of immunocompromised 
individuals. Lung and CNS are two important organs involved by 
Cryptococcus neoformans (Price et al, 2011). Diagnosis is based on direct microscopic 
examination of India ink preparations and PCR (Ndiaye et al, 2011; Sidrim et al, 2010; 
Mseddi et al, 2011). Amphotericin B and flucytosine is used for treatment (Thalla et al, 2009). 
Histoplasmosis (Van Koeveringe & Brouwer, 2010), fusariosis (Campo et al, 2010) and other 
uncommon fungal infection may be seen in immunocomromised patients. 
2.7 Pnemocystis jirovecii infection 
Pneumocystis jiroveci pneumonia (formerly Pneumocystis carinii pneumonia) occurs 
frequently in patients with immunodeficiency (Otahbachi et al, 2007). Pneumocystis carinii 
pneumonia (PCP) in patients with chronic lymphocytic leukaemia (CLL) who have not been 
treated with fludarabin are rare, although clinically relevant CD4 T-cell depletion can occur 
in longstanding CLL without prior treatment with purine analogues (Vavricka et al, 2004). It 
is associated with a wide spectrum of clinical presentations (Gal et al, 2002). The most 
frequent symptoms are: fever, dyspnea, non-productive cough, thoracic pain, chills and 
severe hypoxaemia (Pagano et al, 2002). For diagnosis of PCP bronchoalveolar lavage (BAL) 
cytology and transbronchial lung biopsy (TBLB) may be required (Bijur et al, 1996). Because 
Pneumocystis cannot be cultured, diagnosis relies on detection of the organism by 
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colorimetric or immunofluorescent stains or by polymerase chain reaction. Trimethoprim-
sulfamethoxazole is the preferred drug regimen for both treatment and prevention of PCP, 
although a number of alternatives are also available. Corticosteroids are an important 
adjunct for hypoxemic patients (Kovacs et al, 1994). 
2.8 Mycobacterium avium complex infection 
Mycobacterium avium complex (MAC) primarily causes respiratory infection in patients with 
underlying lung disease or disseminated disease in immunocompromised patients (Azzam et 
al, 2009). MAC is clinically important since it can cause severe infections in 
immunocompromised individuals (Rodrigues et al, 2009). Severe lymphopenia is one of the 
most profound hematologic effects of alemtuzumab, often predisposing patients to infectious 
complications such as herpes simplex virus, cytomegalovirus, and Pneumocystis jirovecii 
pneumonia. Opportunistic infections secondary to mycobacterial sources like mycobacterium 
avium complex have been documented less frequently (Saadeh & Srkalovic, 2008). A diagnosis 
requires a high index of suspicion in patients with immunocompromised status who present 
with prolonged fever, with or without organ-specific symptoms and signs. Therefore, clinical 
specimens must be sent for mycobacterial cultures for a definite diagnosis (Saritsiri et al, 2006). 
Microscopic evaluation, culture and PCR may be necessary for diagnosis (Haas et al, 1998). 
Combination of clarithromycin, rifabutin and ethambutol has proven to be the most efficacious 
therapy and therefore it is considered as standard therapy for disseminated MAC infection. 
Clarithromycin, rifabutin and azithromycin given as primary prophylaxis can diminish the 
risk of disseminated MAC infection (Fätkenheuer et al, 1998).  
2.9 Adenovirus infection 
Adenovirus infections are widespread in society and are occasionally associated with severe, 
but rarely with life-threatening, disease in otherwise healthy individuals. In contrast, 
adenovirus infections present a real threat to immunocompromised individuals and can result 
in disseminated and fatal disease (Andersson et al, 2010). It is an important cause of morbidity 
and mortality in the immunocompromised host (Gavin & Katz, 2002). Adenovirus infection has 
been reported following alemtuzumab treatment in CLL patients (Martin et al, 2006). There is 
no formally approved treatment of adenovirus infections today, and existing antiviral agents 
evaluated for their antiadenoviral effect give inconsistent results (Andersson et al, 2010). 
ribavirin and cidofovir are used for treatment of adenovirus infection (Gavin & Katz, 2002). 
2.10 Other microorganism infection 
Other opportunistic and non-opportunistic organisms like toxoplamosis, tuberculosis, non 
tuberculosis mycobacteria, herpes zoster infection, etc may infect CLL patients (Herrero et 
al, 1995; Mehta et al, 1997; Juliusson & Liliemark, 1996;  Krebs et al, 2000) 
3. Management 
3.1 Diagnosis 
Appropriate diagnosis is important for treatment. Different diagnostic methods may be 
needed to achieve diagnosis. Culture (blood, urine, sputum, etc.), search for antigens 
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(Legionella pneumophila serogroup 1, galactomannan, and Streptococcus pneumonia), CSF 
analysis, radiologic modality (x-ray, CT scan, MRI, etc.), broncoscopy, endoscopy, tissue 
biopsy and other diagnostic test may be used to find the etiologic agents (Batlle et al., 2001; 
Krebs et al, 2000). 
3.2 Treatment 
Appropriate antibacterial, antiviral and anti fungal treatment can be life saving (for specific 
treatment of each microorganism see above). Immunoglobulins are an important component 
of host defense against infections. They also play a central role in immune regulation. A 
wide spectrum of human diseases is associated with decreased or abnormal regulation of 
immunoglobulin levels. Recently intravenous (IV) preparations of immunoglobulin have 
become available for clinical studies. There are already substantial data indicating a useful 
role for IV immunoglobulin in patients with primary hypogammaglobulinemia, neonates 
predisposed to group B streptococcal infections, individuals with ITP, children with 
Kawasaki disease, bone marrow transplant patients predisposed to CMV infections and in 
individuals with CLL (Berkman et al, 1988). Intravenous immunoglobulin (IVIG) 
replacement therapy reduces the number of bacterial infections in CLL patients. However, 
due to the complexity of immunodeficiency in CLL and the cost-effectiveness of 
replacement therapy, it is important to identify patients who are likely to benefit from the 
treatment and to investigate which dose should be used. Low dose of gammaglobulin 
intravenously can restore normal serum IgG levels in hypogammaglobulinaemic B-CLL 
patients, and leads to a decreased number of febrile episodes and admissions to hospital due 
infections (Jurlander et al, 1994, 1995). IVIG has been shown to be a useful prophylactic 
therapy against infections (Gamm et al, 1994). Granulocyte colony stimulating factor (G-
CSF) supplementation may improve the rate of infectious complications by reducing the 
duration of drug-induced neutropenia (Südhoff et al, 1997). It can be used safely and 
effectively in CLL-patients with severe bacterial infections to restore neutropenia (Hollander 
et al, 1991). Granulocyte macrophage colony stimulating factor (GM-CSF) is also effective in 
improving CLL associated chronic neutropenia and also enhances impaired granulocyte 
chemiluminescence. Thus, GM-CSF could be helpful for giving chemotherapy without 
neutropenic delays and for prophylaxis of infectious complications in CLL patients (Itälä et 
al, 1996, 1998). 
3.3 Prophylaxis  
Patients with advanced disease who receive cytotoxic therapy may benefit from 
antibacterial prophylaxis. Risk of infection can potentially be reduced by administration of 
intravenous immunoglobulin and use of prophylactic antibiotics for individuals who are at 
high risk (5). Treatments of CLL enhance the risk of myelosuppression and infection, so 
these patients may need antibiotic, antiviral, and antimycotic prophylaxis during and after 
their administration (Todisco, 2009). Antimicrobial prophylaxis, particularly anti-
Pneumocystis prophylaxis, may be indicated in selected patients (Young, 2011). 
Consideration of primary prophylaxis against M. avium complex infections in aggressively 
treated patients with advanced B-CLL or other clinical indications may be warranted 
(Saadeh & Srkalovic, 2008). Some investigators recommend routine antibacterial and 
antiviral prophylaxis during and after purine nucleoside analogues treatment (Perkins et al., 
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2002). An understanding of the patients at highest risk and duration of risk are important in 
developing recommendations for empirical management, antimicrobial prophylaxis and 
targeted surveillance (Thursky et al, 2006). 
3.4 Vaccination 
Routine vaccination should be maintained in CLL patients and vaccination early in the 
course of treatment may result in improve protection (Young, 2011). Antibody response 
rates to vaccine antigens are lower in patients with CLL compared to normal host. However, 
if the vaccine has been administered at an early stage of the disease and before starting 
chemotherapy and the development of hypogammaglobulinaemia, a significant vaccination 
response to antigens will be obtained in almost 40% of the CLL patients. Early 
administration of vaccine may be beneficial in CLL patients (Sinisalo et al., 2007). Bacterial 
polysaccharide vaccines would seem to be ineffective in antibody formation in patients with 
CLL. However, protein and conjugate vaccines appear to be more immunogenic and their 
responses may be further enhanced with ranitidine adjuvant treatment (Sinisalo et al, 2003). 
Response rate to Haemophilus influenzae type b (Hib) conjugate vaccine among adult and 
elderly patients with chronic lymphocytic leukaemia was 43% in Sinsalo’s study (Sinsalo et 
al, 2002). It is recommended to vaccinate CLL patients with S. pneumoniae and 
Haemophilus influenzae type b (Hib) vaccines as soon as the diagnosis of CLL is made, 
early in the course of the disease with determination of post-vaccination antibody levels 
(Hartkamp et al, 2001). Antibody production after vaccination against common pathogen in 
CLL patients may improve by treatment histamine type-2 receptor blockade such as 
ranitidine (Jurlander et al, 1994, 1995). Influenza vaccination is recommended for patients 
with B-cell CLL however immune response to influenza vaccination appears to be poor (Van 
der Velden et al, 1995). New well-designed investigations are needed to develop 
appropriate vaccination strategies and evaluate vaccination efficacy in infection morbidity 
and mortality in CLL (Sinisalo et al, 2003). 
4. Conclusion 
Infectious complications are leading causes of morbidity and mortality in CLL patients. 
High index of suspicious and using appropriate diagnostic methods, treatment and 
prophylaxis can enhance survival of patients. 
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